Untangling BRCA mutations, sex hormones, and cancer risk
Cette étude cas-témoins évalue le niveau sérique des hormones sexuelles et l'épaisseur de l'endomètre au cours du cycle menstruel en fonction de la présence ou non de mutations des gènes BRCA1 ou BRCA2 (228 cas et 754 témoins)
Understanding basic disease mechanisms might allow development of novel strategies for the primary prevention of breast and ovarian cancer. For carriers of BRCA1/2 mutations, options for primary prevention are limited to bilateral salpingo-oophorectomy and prophylactic mastectomy. In The Lancet Oncology , Martin Widschwendter and colleagues 1 compare ovarian and endometrial function in carriers of the BRCA1/2 mutation with high-risk, mutation negative women in the UK Familial Ovarian Cancer Screening St ...
The Lancet Oncology 2013